Back to results
US 9,040,462 B2Granted
In vivo production of cyclic peptides for inhibiting protein-protein interaction
AssigneeRigel Pharmaceuticals, Inc.
InventorsJames B. Lorens, Todd R. Pray, Todd M. Kinsella, Mark K. Bennett
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.
Claims18
A method comprising:
- a) introducing a library of fusion nucleic acids into a plurality of cells, wherein said cells comprise a first interacting protein and a second interacting protein and wherein said library of fusion nucleic acids comprises, from 5′ to 3′:
- i) nucleic acid encoding a C-terminal intein motif;
- ii) nucleic acid encoding a peptide;
- and
- iii) nucleic acid encoding an N-terminal intein motif;
- wherein said introducing provides for production of a cyclic peptide in said cells;
- and;
- b) identifying a cell comprising a cyclic peptide capable of preventing interaction of said interacting proteins.
5 more elements
Dependencies are inferred from the claim text.